Skip to main content
. Author manuscript; available in PMC: 2009 Aug 1.
Published in final edited form as: Toxicol Appl Pharmacol. 2008 Mar 12;230(3):383–389. doi: 10.1016/j.taap.2008.03.003

Figure 2.

Figure 2

As(III) and MMA(III) activate the endogenous Nrf2-dependent antioxidant response. (A) UROtsa cells were treated with the indicated concentrations of As(III) (left panel) or MMA(III) (right panel) for 16 h. The endogenous Nrf2 and α-tubulin protein levels were detected by immunoblot analysis with anti-Nrf2 and anti-α-tubulin antibodies. (B) UROtsa cells were treated for 16 h with 10 µM As(III), 1 µM MMA(III), 50 µM tBHQ, or 7.5 µM SF. The mRNA levels of Nrf2, HO-1, and NQO1, were determined by real-time PCR. (C) UROtsa cells were either left untreated (control) or treated with 20 µM As(III) or 2 µM MMA(III) for 4 h. Cycloheximide (50 µM) was added and cell lysates were collected at the indicated time points and subjected to immunoblot analysis with anti-Nrf2 and anti-α-tubulin antibodies. The relative intensities of the Nrf2 bands were quantified by the ChemiDoc XRS gel documentation system from Bio-Rad and plotted on a semi-log scale. The half-life of Nrf2 in each group was indicated.

HHS Vulnerability Disclosure